Ciril Rozman

Ciril Rozman

Auto-generated profile, based on publicly available information

Ciril Rozman

Department of Haematology, Hospital Clínic i Provincial, Barcelona

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2002
Verified
Journal Article
Closed access
JSJorge Sierra
Jorge Sierra
WPWaleska S Pérez
Waleska S Pérez
CRCiril Rozman
Ciril Rozman
ECEnric Carreras
Enric Carreras
JKJohn P Klein
John P Klein
MHMary M Horowitz
Mary M Horowitz

1 January 2001 in The Hematology Journal
Verified
Journal Article
Closed access
Joan BladéJoan Bladé
Joan Bladé
JMJesús F San Miguel
Jesús F San Miguel
MFMontserrat Fontanillas
Montserrat Fontanillas
JEJordi Esteve
Jordi Esteve
JMJuan Maldonado
Juan Maldonado
EMEmili Montserrat
Emili Montserrat

1 September 2001 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
SBSalut Brunet
Salut Brunet
AUAlvaro Urbano‐Ispizua
Alvaro Urbano‐Ispizua
EOEmilio Ojeda
Emilio Ojeda
DRDolores Ruiz
Dolores Ruiz
JMJosé Ma. Moraleda
José Ma. Moraleda
SPSpain
Spain
To assess the influence of graft‐versus‐host disease (GVHD) on the outcome of patients with advanced haematological malignancies (AHM) who received a primary, unmodified allogeneic peripheral blood progenitor cells transplant (allo‐PBT) from a human leucocyte antigen (HLA) identical sibling donor, we analysed 136 patients with myeloid neoplasms (n = 70) or lymphoproliferative disorders (n = 66), transplanted at 19 Spanish institutions. Median age was 35 years (range 1–61). The cumulative incidence of relapse for all patients was 34% (95% CI, 26–42%), 41% (95% CI, 33–49) for patients without GVHD and 14% (95% CI, 3–25) (P = 0·001) for patients with acute and chronic GVHD. After a median follow‐up of 11 months (range 2–49), 60 (44%) patients remained alive with an actuarial probability of overall survival and disease‐free survival (DFS) at 30 months of 31% (95% CI, 21–41%) and 28% (95% CI, 17–39%) respectively. In patients surviving > 100 d, the low incidence of relapse in those with acute and chronic GVHD led to a DFS of 57% (95% CI, 38–76%) compared with a DFS of 34% (95% CI, 17–51%) in the remaining patients (P = 0·03). Our results indicate a reduced incidence of relapse for patients with AHM receiving an unmodified allo‐PBT and developing acute and chronic GVHD, which results in an improved DFS.

1 February 1997 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
ECEnric Carreras
Enric Carreras
JSJorge Sierra
Jorge Sierra
MRMontserrat Rovira
Montserrat Rovira
AUAlvaro Urbano-Ispizua
Alvaro Urbano-Ispizua
CMCarmen Martinez
Carmen Martinez
EMEmilio Montserrat
Emilio Montserrat
Several non‐randomized studies suggest a possible survival advantage for chronic myelogenous leukaemia (CML) patients treated with an autologous stem‐cell transplantation. Due to the possible contribution of residual leukaemic cells present in the inoculum in post‐transplant relapse, several methods are being evaluated to eliminate neoplastic cells or to select ‘normal’ (Ph1 negative) progenitor cells for autografting. Recently, several studies have shown that Ph1 negative blood progenitor cells can be mobilized by rHuG‐CSF alone in patients who have a cytogenetic response to alpha‐interferon (IFN). We describe the first case, as far as we are aware, of a CML patient responding to IFN autografted by using blood progenitor cells collected by rHuG‐CSF alone.

1 January 1998 in Hematology
Verified
Journal Article
Closed access
ECEnric Carreras
Enric Carreras
CRCiril Rozman
Ciril Rozman
Veno-occlusive disease of the liver (VOD) was originally described in patients who drank infusions made with plants containing pyrrolizidine alkaloids [1]. This disease was characterized, histologically, by a progressive and concentric non-thrombotic narrowing of the lumina of small intrahepatic veins. Later, VOD was related to other pathogens such as alcohol, contraceptives, toxic oil, liver radiation and several antineoplastic drugs [2–3]. The first case of veno-occlusive disease following bone marrow transplantation (BMT) was reported in 1979 [4]. Since then, BMT has proved to be the main cause of VOD which is one of the leading causes of morbidity and mortality after transplant [5–7]. Clinical manifestations of VOD are very characteristic (jaundice, painful hepatomegaly and fluid retention) but indistinguishable from those produced by other regime-related morphological changes on zone 3 of the liver acinus. For this reason, the term “syndrome of veno-occlusive disease of the liver” has been adopted to designate the clinical manifestations of conditioning regimen toxicity on this zone [8]. This review focuses on the present knowledge of VOD syndrome after BMT.